EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Beyond the Fragility Index

Piero Quatto, Enrico Ripamonti iD, Donata Marasini

Pharmaceutical Statistics · 2025

DOI: 10.1002/pst.2452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2025. Verfasst von Piero Quatto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Economics, Management and Statistics, University of Milan-Bicocca, Milan, Italy. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Research Design, Data Interpretation, Statistical, Computer Simulation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The results of randomized clinical trials (RCTs) are frequently assessed with the fragility index ( FI ). Although the information provided by FI may supplement the p value, this indicator presents intrinsic weaknesses and shortcomings. In this article, we establish an analysis of fragility within a broader framework so that it can reliably complement the information provided by the p value. This perspective is named the analysis of strength . We first propose a new strength index ( SI ), which can be adopted in normal distribution settings. This measure can be obtained for both significance and nonsignificance and is straightforward to calculate, thus presenting compelling advantages over FI , starting from the presence of a threshold. The case of time‐to‐event outcomes is also addressed. Then, beyond the p value, we develop the analysis of strength using likelihood ratios from Royall's statistical evidence viewpoint. A new R package is provided for performing strength calculations, and a simulation study is conducted to explore the behavior of SI and the likelihood‐based indicator empirically across different settings. The newly proposed analysis of strength is applied in the assessment of the results of three recent trials involving the treatment of COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicResearch DesignData Interpretation, StatisticalComputer SimulationCOVID-19COVID-19 Drug TreatmentModels, StatisticalSARS-CoV-2Likelihood FunctionsHumans

Stichwörter der Autor:innen

fragility indexlikelihood ratiorandomized clinical trialstrength index

Autor:innen und Institutionen

  • Department of Economics, Management and Statistics, University of Milan-Bicocca, Milan, Italy.
  • Milan Center of Neuroscience, University of Milan-Bicocca, Milan, Italy.
  • Bicocca Applied Statistics Center (B-ASC), university of Milan-Bicocca, Milan, Italy.
  • Department of Economics and Management, University of Brescia, Brescia, Italy.

ORCID-Profile: Enrico Ripamonti

Zitieren

APA

Quatto, P., Ripamonti, E., & Marasini, D. (2025). Beyond the Fragility Index. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2452

Vancouver

Quatto P, Ripamonti E, Marasini D. Beyond the Fragility Index. Pharmaceutical Statistics. 2025. doi:10.1002/pst.2452

BibTeX
@article{Quatto2025,
  author = {Quatto, Piero and Ripamonti, Enrico and Marasini, Donata},
  title = {Beyond the Fragility Index},
  journal = {Pharmaceutical Statistics},
  year = {2025},
  doi = {10.1002/pst.2452}
}
Kostenlos starten →